|
|
Volumn 5, Issue 3, 2009, Pages 231-236
|
|
Predicting benefit from statins by C-reactive protein, LDL-cholesterol or absolute cardiovascular risk.
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
BIOLOGICAL MARKER;
C REACTIVE PROTEIN;
FLUOROBENZENE;
HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;
LOW DENSITY LIPOPROTEIN CHOLESTEROL;
PYRIMIDINE DERIVATIVE;
ROSUVASTATIN;
SULFONAMIDE;
ARTICLE;
BLOOD;
CARDIOVASCULAR DISEASE;
CLINICAL TRIAL;
CONFIDENCE INTERVAL;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
DRUG EFFECT;
FEMALE;
HUMAN;
HYPERCHOLESTEROLEMIA;
MALE;
MIDDLE AGED;
RANDOMIZED CONTROLLED TRIAL;
RISK;
RISK ASSESSMENT;
RISK FACTOR;
RISK REDUCTION;
VENOUS THROMBOEMBOLISM;
BIOLOGICAL MARKERS;
C-REACTIVE PROTEIN;
CARDIOVASCULAR DISEASES;
CHOLESTEROL, LDL;
CONFIDENCE INTERVALS;
FEMALE;
FLUOROBENZENES;
HUMANS;
HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS;
HYPERCHOLESTEROLEMIA;
MALE;
MIDDLE AGED;
PYRIMIDINES;
RISK;
RISK ASSESSMENT;
RISK FACTORS;
RISK REDUCTION BEHAVIOR;
SULFONAMIDES;
VENOUS THROMBOEMBOLISM;
|
|
EID: 70449723133
PISSN: None
EISSN: 17448298
Source Type: Journal
DOI: 10.2217/fca.09.8 Document Type: Article |
|
Times cited : (6)
|
|
References (0)
|
